Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Atrium Therapeutics Inc. > Profile

Atrium Therapeutics Inc. (RNA)

Market is closed
Sector: Pharmaceutical Preparations

Insider Roster

Show All Insiders (11)
News See All
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?

Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?

On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc.

Keep Reading →

August 28th, 2026 - Hedge Funds News

Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger

Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger

Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025.

Keep Reading →

February 27th, 2026 - News

15 Stocks with the Biggest Hedge Fund Momentum

15 Stocks with the Biggest Hedge Fund Momentum

On February 23, Bloomberg News reported that during the week ended February 19, hedge funds registered record-high net sales of global stocks, the highest since early April 2025.

Keep Reading →

February 27th, 2026 - Hedge Funds News

Avidity Biosciences, Inc. (RNA): A Bull Case Theory 

We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by  AnotherBio. In this article, we will summarize the bulls’ thesis on RNA.

Keep Reading →

December 4th, 2025 - News Stock Analysis

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger

Earlier in the week, Novartis said it entered into an agreement with Avidity Biosciences, Inc.

Keep Reading →

November 3rd, 2025 - News

Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis

Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis

In a statement over the weekend, Novartis said that it entered into an agreement with Avidity Biosciences, Inc.

Keep Reading →

October 28th, 2025 - News

What Makes Avidity Biosciences (RNA) an Investment Choice?

What Makes Avidity Biosciences (RNA) an Investment Choice?

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.

Keep Reading →

October 13th, 2025 - Hedge Fund Investor Letters News

11 Best Performing Long Term Stocks According to Analysts

11 Best Performing Long Term Stocks According to Analysts

Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000.

Keep Reading →

September 23rd, 2025 - Hedge Funds News

Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating

Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating

In a market note, BofA Securities gave a “buy” recommendation for Avidity Biosciences Inc.’s (NASDAQ:RNA) stock with a price target of $65, an increase from the $56 previously.

Keep Reading →

September 13th, 2025 - News

11 Best Stocks to Buy for the Next 3 Months According to Hedge Funds

11 Best Stocks to Buy for the Next 3 Months According to Hedge Funds

On September 6, Rebecca Patterson, Chief Investment Strategist at Bridgewater Associates, appeared in an interview on CNBC to discuss the current US economy.

Keep Reading →

September 9th, 2025 - Hedge Funds News

Click here to See All News
Insider Monkey Quarterly Strategy
+599.2% Insider Monkey Quarterly Strategy
+227% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF
500%
250%
0%

Returns since its inception in May 2014 (through June 2, 2026)

Subscribe Now

30 day money back guarantee. Cancel anytime.

Past performance does not guarantee future returns. Click to see how the portfolio is constructed.